The Technical Analyst
Entasis Therapeutics [ETTX]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Entasis Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $2.19
/ 4 apr 2024 @ 16:00
| RATING 2022-07-11 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.950 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.950 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.16 - 2.22 ( +/- 1.46%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-07-08 | Innoviva Strategic Opportunities Llc | Buy | 7 598 814 | Common Stock |
| 2022-07-07 | Tommasi Ruben | Sell | 39 596 | Common Stock |
| 2022-07-11 | Tommasi Ruben | Sell | 150 000 | Common Stock |
| 2022-07-11 | Tommasi Ruben | Sell | 98 700 | Stock Option (right to buy) |
| 2022-07-11 | Tommasi Ruben | Sell | 50 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 54.66 |
| Last 98 transactions |
| Buy: 9 607 238 | Sell: 3 128 729 |
Forecast:
01:40 - $2.20
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.19 (0.00% ) |
| Volume | 0.0688 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ETTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ETTX
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Latest Press Releases
2022-07-08 08:35:00 - Press Release
Innoviva Announces Expiration Of Cash Tender Offer For Shares Of Entasis Therapeutics Holdings Inc.
Burlingame, calif.--(business wire)--innoviva, inc. (nasdaq: inva) (“innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of entasis therapeutics holdings inc. (nasdaq: ettx) (“entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. new york city time on thursday, july 7, 2022. the depositary for the tender offer has advised that, as of the exp
2022-06-03 11:30:00 - Press Release
Scott+scott Attorneys At Law Llp Investigates Innoviva Buyout Of Entasis – Ettx
New york--(business wire)--scott+scott attorneys at law llp (“scott+scott”), an international securities and consumer rights litigation firm, is investigating whether the directors of entasis therapeutics holdings inc. (“entasis”) (nasdaq: ettx) breached their fiduciary duties to its shareholders in approving a buyout with innoviva, inc. (“innoviva”) (nasdaq: inva) for inadequate consideration. if you are an entasis shareholder, you may contact attorney joe pettigrew for additional information
2022-05-24 18:36:00 - Press Release
Alert: Rowley Law Pllc Is Investigating Proposed Acquisition Of Entasis Therapeutics Holdings Inc.
New york , may 24, 2022 /prnewswire/ -- rowley law pllc is investigating potential securities law violations by entasis therapeutics holdings inc. (nasdaq: ettx) and its board of directors concerning the proposed acquisition of the company by innoviva, inc. (nasdaq: inva). stockholders will receive $2.20 for each share of entasis therapeutics holdings stock that they hold.
2022-05-23 14:25:00 - Press Release
Entasis Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Entasis Therapeutics Holdings Inc. - Ettx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of entasis therapeutics holdings inc. (nasdaqgm: ettx) to innoviva, inc. (nasdaqgs: inva). under the terms of the proposed transaction, shareholders of entasis will receive only $2.20 in cash for each share of entasis that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the company. if you believe that this transaction undervalues the company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call ksf managing partner lewis s...
2022-05-23 10:30:00 - Press Release
Ettx Stock Alert: Halper Sadeh Llp Is Investigating Whether The Sale Of Entasis Therapeutics Holdings Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llp, an investor rights law firm, is investigating whether the sale of entasis therapeutics holdings inc. (nasdaq: ettx) to innoviva, inc. for $2.20 per share in cash is fair to entasis shareholders. halper sadeh encourages entasis shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. the investigation concerns whether entasis and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for entasis shareholders; (2) determine whether innoviva is underpaying for entasis; and (3) disclose all material information necessary for entasis shareholders to adequately assess and value the merger consideration...
Latest News
2022-05-24 16:34:09 - Zacks Investment Research
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva
Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.
2022-05-23 10:17:08 - Benzinga
Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share
Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock.
2022-03-16 12:15:15 - InvestorPlace
Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today
We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about! The post Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today appeared first on InvestorPlace.
2021-11-06 15:50:08 - Seeking Alpha
Entasis Therapeutics Holdings Inc. (ETTX) CEO Manoussos Perros on Q3 2021 Results - Earnings Call Transcript
Entasis Therapeutics Holdings Inc. (ETTX) CEO Manoussos Perros on Q3 2021 Results - Earnings Call Transcript
2021-10-18 16:05:00 - GlobeNewsWire
Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial
WALTHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results...
2021-09-23 16:05:00 - GlobeNewsWire
Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference
WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming Cantor Fitzgerald Virtual Global Healthcare Conference to be held September 27-30, 2021.
2021-09-20 16:34:27 - PennyStocks
Making Money With Penny Stocks During a Stock Market Crash
Trading penny stocks in a down market? Here's three tips and tricks to use in your search The post Making Money With Penny Stocks During a Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-09-16 14:28:49 - Benzinga
Why Are Entasis Therapeutics Shares Moving Higher On Thursday?
Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) stock is up sharply after the journal Nature published an article on the potential of its preclinical candidate ETX0462, which could become the first of a new class of antibiotics. ETX0462 is under development for multidrug-resistant Gram-negative and biothreat infections.
2021-09-15 16:01:00 - GlobeNewsWire
Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature
Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens
2021-08-12 11:25:08 - Seeking Alpha
Entasis Therapeutics Holdings Inc. (ETTX) CEO Manoussos Perros on Q2 2021 Results - Earnings Call Transcript
Entasis Therapeutics Holdings Inc. (ETTX) CEO Manoussos Perros on Q2 2021 Results - Earnings Call Transcript